Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22093206 | 0.75 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL24102575 | 0.73 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL24102626 | 0.72 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL2653451 | 0.71 | — | — | |
| SCHEMBL13560597 | 0.71 | CPB2 (0.37) | DGAT1 | |
| SCHEMBL2822834 | 0.70 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL27089125 | 0.69 | — | — | |
| SCHEMBL25130068 | 0.69 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL24102560 | 0.69 | DGAT1 (0.30) | DGAT1 | |
| SCHEMBL14151668 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7081466-B2 | 2-aroylimidazole compounds for treating cancer | SYNTA PHARMACEUTICALS CORP. (US) | 2006-07-25 | — | — | US | disclosed |
| US-20040186129-A1 | 2-Aroylimidazole compounds for treating cancer | KOYA KEIZO (US) | 2004-09-23 | — | — | US | disclosed |
| EP-1427413-A2 | 2-AROYLIMIDAZOLE COMPOUNDS FOR TREATING CANCER | Synta Pharmaceuticals Corporation (US) | 2004-06-16 | — | — | EP | disclosed |
| US-6743919-B2 | INCLUDING MULTI-DRUG RESISTANT CANCER CELLS FROM A NUMBER OF DIFFERENT TISSUE TYPES | SYNTA PHARMACEUTICALS CORP. | 2004-06-01 | — | — | US | disclosed |
| US-20030096836-A1 | 2-Aroylimidazole compounds for treating cancer | SBR PHARMACEUTICALS CORP. | 2003-05-22 | — | — | US | disclosed |
| WO-2003022274-A2 | 2-AROYLIMIDAZOLE COMPOUNDS FOR TREATING CANCER | SYNTA PHARMACEUTICALS CORP. (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096836-A1 | 2-Aroylimidazole compounds for treating cancer | NR4A1, NR0B2, NR0B1 | DGAT1 3518/4885 |
| US-20040186129-A1 | 2-Aroylimidazole compounds for treating cancer | TOP2B, HDAC11, CYP4B1 | DGAT1 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.